3.3800
-0.1900
(-5.31%)
As of 12:23:12 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.29 | -0.25 | -1.04 | -1.13 |
| Low Estimate | -0.3 | -0.29 | -1.21 | -1.51 |
| High Estimate | -0.27 | -0.22 | -0.95 | -0.88 |
| Year Ago EPS | -0.2 | -0.22 | -1.09 | -1.04 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.3 | -0.26 | -0.29 | -0.33 |
| EPS Actual | -0.2 | -0.22 | -0.33 | -0.29 |
| Difference | 0.1 | 0.04 | -0.04 | 0.04 |
| Surprise % | 33.33% | 16.45% | -13.79% | 12.12% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.29 | -0.25 | -1.04 | -1.13 |
| 7 Days Ago | -0.34 | -0.26 | -0.94 | -0.93 |
| 30 Days Ago | -0.34 | -0.26 | -0.94 | -0.93 |
| 60 Days Ago | -0.39 | -0.31 | -1.46 | -1.67 |
| 90 Days Ago | -0.39 | -0.31 | -1.46 | -1.67 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | 1 | 1 |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| THRD | -45.00% | -15.15% | 4.59% | -8.97% |
| S&P 500 | 6.68% | 6.74% | 9.91% | 14.34% |
Upgrades & Downgrades
| Downgrade | Stifel: Buy to Hold | 3/28/2025 |
| Downgrade | Morgan Stanley: Overweight to Equal-Weight | 2/12/2025 |
| Downgrade | Raymond James: Outperform to Market Perform | 2/11/2025 |
| Upgrade | Morgan Stanley: Equal-Weight to Overweight | 8/9/2024 |
| Initiated | Stifel: Buy | 6/18/2024 |
| Initiated | Raymond James: Outperform | 6/7/2024 |
Related Tickers
HLVX HilleVax, Inc.
1.4400
-0.69%
EPIX ESSA Pharma Inc.
1.5150
-4.10%
TBPH Theravance Biopharma, Inc.
8.46
-3.59%
KZR Kezar Life Sciences, Inc.
4.0500
-10.00%
KROS Keros Therapeutics, Inc.
9.93
-3.40%
ASMB Assembly Biosciences, Inc.
8.72
-6.34%
ANTX AN2 Therapeutics, Inc.
1.2900
-7.86%
SPRO Spero Therapeutics, Inc.
0.5968
-4.36%
RPTX Repare Therapeutics Inc.
1.0100
-3.81%
GLTO Galecto, Inc.
2.7250
-4.72%